REGN - Embedded Expectations Analysis - 2020 01 22
ï€ Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost managementï€ Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack confidence in their ability to sustain revenue growth and optimize the efficacy and safety profile for their BCMA biospecific programs. Furthermore, management may be downplaying concerns about increases in their SG&A expenses and cost of goods sold, and they may lack confidence in their ability to effectively manage costs across their collaboration with Sanofi. Finally, they may be exaggerating the potential of their new adjuvant CSCC study and PD-1 antibody, Libtayo
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. The company's commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. The company's products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.